A citation-based method for searching scientific literature

J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J Eck, William R Sellers, Bruce E Johnson, Matthew Meyerson. Science 2004
Times Cited: 7488







List of co-cited articles
669 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.
Natalia Jura, Nicholas F Endres, Kate Engel, Sebastian Deindl, Rahul Das, Meindert H Lamers, David E Wemmer, Xuewu Zhang, John Kuriyan. Cell 2009
418
3


CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, Yukako Tachibana, Takashi Chiba, Takuya Torizawa, Hiroshi Sakamoto. Mol Cancer Ther 2020
36
8

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Yuankai Shi, Xingsheng Hu, Shucai Zhang, Dongqing Lv, Lin Wu, Qitao Yu, Yiping Zhang, Li Liu, Xiang Wang, Ying Cheng,[...]. Lancet Respir Med 2021
40
7

Architecture and membrane interactions of the EGF receptor.
Anton Arkhipov, Yibing Shan, Rahul Das, Nicholas F Endres, Michael P Eastwood, David E Wemmer, John Kuriyan, David E Shaw. Cell 2013
336
3

Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
Stepan M Esagian, Georgia Ι Grigoriadou, Ilias P Nikas, Vasileios Boikou, Peter M Sadow, Jae-Kyung Won, Konstantinos P Economopoulos. J Cancer Res Clin Oncol 2020
40
7

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
3

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Peter T Harrison, Simon Vyse, Paul H Huang. Semin Cancer Biol 2020
144
3

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa, Valentina Pirazzoli, Maria E Arcila, Caroline A Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y Janjigian, Paula J Spitzler, Mary Ann Melnick,[...]. Cancer Discov 2012
515
3


Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
James Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, Suresh S Ramalingam, Lecia V Sequist, Wu-Chou Su, Sang-We Kim, Joo-Hang Kim, David Planchard, Enriqueta Felip,[...]. J Clin Oncol 2017
389
3

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Matthew J Niederst, Lecia V Sequist, John T Poirier, Craig H Mermel, Elizabeth L Lockerman, Angel R Garcia, Ryohei Katayama, Carlotta Costa, Kenneth N Ross, Teresa Moran,[...]. Nat Commun 2015
382
3

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
826
3

The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.
Laura C Zanetti-Domingues, Dimitrios Korovesis, Sarah R Needham, Christopher J Tynan, Shiori Sagawa, Selene K Roberts, Antonija Kuzmanic, Elena Ortiz-Zapater, Purvi Jain, Rob C Roovers,[...]. Nat Commun 2018
48
6

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Hyun-Soo Cho, Karen Mason, Kasra X Ramyar, Ann Marie Stanley, Sandra B Gabelli, Dan W Denney, Daniel J Leahy. Nature 2003
3

Inflammation and cancer.
Lisa M Coussens, Zena Werb. Nature 2002
3

STAR: ultrafast universal RNA-seq aligner.
Alexander Dobin, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, Thomas R Gingeras. Bioinformatics 2013
3

Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Francisco Sanchez-Vega, Marco Mina, Joshua Armenia, Walid K Chatila, Augustin Luna, Konnor C La, Sofia Dimitriadoy, David L Liu, Havish S Kantheti, Sadegh Saghafinia,[...]. Cell 2018
3

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
3


Mechanisms of receptor tyrosine kinase activation in cancer.
Zhenfang Du, Christine M Lovly. Mol Cancer 2018
313
3

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
Maria E Arcila, Geoffrey R Oxnard, Khedoudja Nafa, Gregory J Riely, Stephen B Solomon, Maureen F Zakowski, Mark G Kris, William Pao, Vincent A Miller, Marc Ladanyi. Clin Cancer Res 2011
451
3

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Lecia V Sequist, Renato G Martins, David Spigel, Steven M Grunberg, Alexander Spira, Pasi A Jänne, Victoria A Joshi, David McCollum, Tracey L Evans, Alona Muzikansky,[...]. J Clin Oncol 2008
673
3

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.
Chao-Chi Ho, Wei-Yu Liao, Chih-An Lin, Jin-Yuan Shih, Chong-Jen Yu, James Chih-Hsin Yang. J Thorac Oncol 2017
152
3

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba,[...]. Lung Cancer 2018
43
6



Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, Hossein Borghaei, Scott Antonia, Julie R Brahmer, Jonathan W Goldman, David E Gerber, Rosalyn A Juergens, Frances A Shepherd,[...]. J Thorac Oncol 2018
115
3

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Shunsuke Kitajima, Elena Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Shriram K Sundararaman, Shoichiro Tange, Yoichiro Mitsuishi, Tran C Thai, Sayuri Masuda,[...]. Cancer Discov 2019
200
3

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kari J Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi, Erik H Knelson, Yingtian Xie, Klothilda Lim, Paloma Cejas,[...]. Cancer Cell 2020
147
3

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
3

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Shuhang Wang, Stella T Tsui, Christina Liu, Yongping Song, Delong Liu. J Hematol Oncol 2016
113
3

Epidermal growth factor receptor (EGFR) signaling in cancer.
Nicola Normanno, Antonella De Luca, Caterina Bianco, Luigi Strizzi, Mario Mancino, Monica R Maiello, Adele Carotenuto, Gianfranco De Feo, Francesco Caponigro, David S Salomon. Gene 2006
3

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
3

EGFR G796D mutation mediates resistance to osimertinib.
Di Zheng, Min Hu, Yu Bai, Xuehua Zhu, Xuesong Lu, Chunyan Wu, Jiying Wang, Li Liu, Zheng Wang, Jian Ni,[...]. Oncotarget 2017
74
4

GSVA: gene set variation analysis for microarray and RNA-seq data.
Sonja Hänzelmann, Robert Castelo, Justin Guinney. BMC Bioinformatics 2013
3


Somatic mutations affect key pathways in lung adenocarcinoma.
Li Ding, Gad Getz, David A Wheeler, Elaine R Mardis, Michael D McLellan, Kristian Cibulskis, Carrie Sougnez, Heidi Greulich, Donna M Muzny, Margaret B Morgan,[...]. Nature 2008
3

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Hyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, Justina X Caushi, Rui Zhao, Matthew M Hims, Angad P Singh, Iris Kao, Daniel Rakiec, Pamela Shaw,[...]. Nat Med 2015
274
3

Lazertinib: First Approval.
Sohita Dhillon. Drugs 2021
19
15

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T Chang, Andy Ni, Ritika Kundra, Philip Jonsson,[...]. Cancer Discov 2017
358
3


Overcoming therapy resistance in EGFR-mutant lung cancer.
Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters. Nat Cancer 2021
60
5

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.
Rajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, Jianying Zhang, Seiji Yano, Rashelle Ghanem, Walter Wang, Shinji Takeuchi, Koji Fukuda, Nobuyuki Katakami,[...]. Nat Commun 2018
39
7

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura,[...]. Cancer Res 2017
97
3

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.
Erin M Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A Pratilas, Neal Rosen, Nathanael S Gray, Kwok-Kin Wong,[...]. Cancer Discov 2015
153
3


Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
Floriana Morgillo, Carminia Maria Della Corte, Morena Fasano, Fortunato Ciardiello. ESMO Open 2016
246
3


Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.